Secnik Kristina, Yurgin Nicole, Lage Maureen J, McDonald-Everett Cindy
Global Health Outcomes, Eli Lilly and Company, Indianapolis, IN 46285, USA.
J Diabetes Complications. 2007 May-Jun;21(3):181-6. doi: 10.1016/j.jdiacomp.2006.04.003.
The objectives of this study were to compare patterns of blood glucose monitoring among patients with type 2 diabetes initiating therapy with insulin or oral medication and to examine the relationship between the quantity of prescribed monitoring strips and glycemic control.
Data were obtained from the UK General Practice Research Database. Patients were eligible if they were identified as having type 2 diabetes, initiated therapy with insulin or an oral agent, and had 12-month postinitiation data. Differences in patient characteristics and number of test strips prescribed between the insulin (n=347) and oral cohorts (n=2436) were examined. Multivariate regressions examined the relationship between quantity of monitoring and glycemic control for a subset of patients (insulin, n=245; oral, n=1795) with available glycosylated hemoglobin (HbA1c) data.
During the 12-month postinitiation period, patients using insulin were prescribed approximately twice as many test strips compared with those patients using oral medication (149 vs. 78, P<.0001). Multivariate regressions revealed that individuals who initiated insulin therapy and were prescribed enough test strips to test at least once per day in the 6 months prior to the HbA1c test date had, on average, a 0.65% lower HbA1c value (P=.02) compared with individuals who were prescribed fewer test strips.
Results indicate significant differences in the prescription of blood glucose monitoring strips, with patients initiated on insulin prescribed almost twice as many test strips compared with patients initiated on orals. The greater number of blood glucose test strips prescribed was associated with lower HbA1c values for insulin patients.
本研究的目的是比较开始接受胰岛素或口服药物治疗的2型糖尿病患者的血糖监测模式,并研究所开具的监测试纸数量与血糖控制之间的关系。
数据来自英国全科医疗研究数据库。符合条件的患者需被确诊为2型糖尿病,开始接受胰岛素或口服药物治疗,且有起始治疗后12个月的数据。研究了胰岛素治疗组(n = 347)和口服药物治疗组(n = 2436)患者特征及所开具试纸数量的差异。多因素回归分析了一部分有糖化血红蛋白(HbA1c)数据的患者(胰岛素治疗组,n = 245;口服药物治疗组,n = 1795)的监测次数与血糖控制之间的关系。
在起始治疗后的12个月期间,使用胰岛素的患者所开具的试纸数量约为使用口服药物患者的两倍(149对78,P <.0001)。多因素回归分析显示,在HbA1c检测日期前6个月开始接受胰岛素治疗且所开具试纸数量足以保证每天至少检测一次的患者,其HbA1c值平均比所开具试纸较少的患者低0.65%(P = 0.02)。
结果表明血糖监测试纸的处方存在显著差异,开始使用胰岛素治疗的患者所开具的试纸数量几乎是开始使用口服药物患者的两倍。对于胰岛素治疗的患者,所开具的血糖试纸数量越多,HbA1c值越低。